Search

Displaying results 661 - 670 of 1546 in total
  1. Drug

    Inotuzumab ozogamicin

    go.drugbank.com/drugs/DB05889
    ApprovedInvestigational

    Inotuzumab ozogamicin is an antibody-drug conjugate consisting of a humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide. The antibody por...

  2. Drug

    Vortioxetine

    go.drugbank.com/drugs/DB09068
    ApprovedInvestigational

    It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin

  3. Drug

    Chikungunya virus Senegal strain 37997 envelope protein E1

    go.drugbank.com/drugs/DB21767
    ApprovedInvestigational

    One of three components of a recombinant Chikungunya virus vaccine called Vimkunya.

  4. Drug

    Molybdenum

    go.drugbank.com/drugs/DB11137
    ApprovedInvestigational

    Molybdenum is a chemical element with symbol Mo and atomic number 42. As it is not a naturally occuring free metal on Earth, molybdenum is found only in various oxidation states in minerals. Molybdenum is commonly used in metallurgy and ...

    Mixtures: Extra Once A Day, Swiss Total One
  5. Drug

    Racemethionine

    go.drugbank.com/drugs/DB13972
    Approved

    A preparation of methionine that includes a mixture of D-methionine and L-methionine isomers.

    Mixtures: Extra Once A Day, Only One - Tablet
  6. Drug

    Calcium levulinate

    go.drugbank.com/drugs/DB13800
    Approved

    The relatively new calcium levulinate is produced from a direct reaction between L- or levulinic acid levulose and calcium hydroxide . The resultant calcium levulinate formulation, when used as a calcium supplement, possesses a high calc...

  7. Drug

    Ociperlimab

    go.drugbank.com/drugs/DB18947
    Investigational

    Ociperlimab is under investigation in clinical trial NCT04866017 (A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (Ccrt) in Patients With Stage

  8. Drug

    Nateglinide

    go.drugbank.com/drugs/DB00731
    Approved

    One minor metabolite, the isoprene, has the same potency as its parent compound. … Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight.

  9. Drug

    Rabies immune globulin, human

    go.drugbank.com/drugs/DB11603
    Approved

    Since rabies vaccine-induced antibody begins to appear within one week, there is no value in administering rabies immune globulin more than eight days after rabies vaccination has begun.

  10. Drug

    Cobicistat

    go.drugbank.com/drugs/DB09065
    ApprovedInvestigational

    More specifically, cobicistat is indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1